Steroids regulate CXCL4 in the human endometrium during menstruation to enable efficient endometrial repair by Maybin, Jacqueline A. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Steroids regulate CXCL4 in the human endometrium during
menstruation to enable efficient endometrial repair
Citation for published version:
Maybin, JA, Thiruchelvam, U, Madhra, M, Saunders, P & Critchley, H 2017, 'Steroids regulate CXCL4 in the
human endometrium during menstruation to enable efficient endometrial repair', Journal of Clinical
Endocrinology & Metabolism, vol. 102, no. 6, pp. 1851-1860. https://doi.org/10.1210/jc.2016-3604
Digital Object Identifier (DOI):
10.1210/jc.2016-3604
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Clinical Endocrinology & Metabolism
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
1 
 
Steroids regulate CXCL4 in the human endometrium during 1 
menstruation to enable efficient endometrial repair. 2 
 3 
Maybin JA1+, Thiruchelvam U1,3+, Madhra M1, Saunders PTK2 and Critchley HOD1*. 4 
 5 
1MRC Centre for Reproductive Health & 2MRC Centre for Inflammation Research, The University of 6 
Edinburgh, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 5TJ.  7 
3Current address: GlasxoSmithKline, GSK House, 980 Great West Road, Brentford, Middlesex, TW8 8 
9GS.  +JAM and UT contributed equally to this work 9 
 10 
Abbreviated title: CXCL4 at menstruation 11 
Key words: macrophage, cortisol, progesterone, heavy menstrual bleeding, menorrhagia, 12 
menstruation. 13 
Word count: 3823 14 
Number of figures and tables: 6 (5 Figures, 1 Table). 15 
*Corresponding author: Professor Hilary OD Critchley, MRC Centre for Reproductive Health, The 16 
University of Edinburgh, Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, 17 
EH16 5TJ. Phone: ++441312426858, Fax: ++441312426441, Email: hilary.critchley@ed.ac.uk 18 
 19 
Funders: This work was undertaken in the MRC Centre for Reproductive Health which is funded by 20 
MRC Centre Grant G1002033 and MR/N022556/1; MRC Grant G0600048 (HODC); Wellcome Trust 21 
100646/Z/12/Z (JAM). MRC Programme Grant G1100356/1 (PTKS).  22 
Disclosure Statement: JAM, MM, PTKS have nothing to disclose. HODC has clinical research 23 
support for laboratory consumables and staff from Bayer Pharma Ag and provides consultancy advice 24 
(but with no personal remuneration) for Bayer Pharma Ag, PregLem SA, Gedeon Richter, Vifor 25 
Pharma UK Ltd, AbbVie Inc.  UT is currently employed with GSK but was not at time of the work 26 
undertaken.   27 
2 
 
Abstract  28 
Context: Repair of the endometrial surface at menstruation must be efficient to minimize blood loss 29 
and optimize reproductive function. The mechanism and regulation of endometrial repair remain 30 
undefined.   31 
Objective: To determine the presence/regulation of CXCL4 in the human endometrium, as a putative 32 
repair factor at menses.  33 
Patients/Setting: Endometrium was collected throughout the menstrual cycle from healthy women 34 
attending the gynecology department. Menstrual blood loss was objectively measured in a subset and 35 
heavy menstrual bleeding (HMB) defined as >80ml/cycle. Monocytes were isolated from peripheral 36 
blood. 37 
Design: CXCL4 mRNA and protein were identified by RT-qPCR and immunohistochemistry. The 38 
function/regulation of endometrial CXCL4 was explored by in vitro cell culture.  39 
Results: CXCL4 mRNA concentrations were significantly increased during menstruation. Intense 40 
staining for CXCL4 was detected in late secretory and menstrual tissue, localized to stromal, 41 
epithelial and endothelial cells. Co-localization identified positive staining in CD68+ macrophages.  42 
Treatment of human endometrial stromal (hESC) and endothelial (HEEC) cells with steroids revealed 43 
differential regulation of CXCL4. Progesterone withdrawal resulted in significant increases in CXCL4 44 
mRNA and protein in hESCs, whereas cortisol significantly increased CXCL4 in HEECs. In women 45 
with HMB, CXCL4 was reduced in endothelial cells during the menstrual phase when compared to 46 
women with normal menstrual bleeding. Cortisol exposed macrophages displayed increased 47 
chemotaxis towards CXCL4 compared to macrophages incubated with estrogen or progesterone.  48 
Conclusions: Our data implicate CXCL4 in endometrial repair post menses. Reduced cortisol at time 49 
of menses may contribute to delayed endometrial repair and HMB, in part by mechanisms involving 50 
aberrant expression of CXCL4.  51 
  52 
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Introduction 53 
 54 
The human endometrium displays a remarkable ability to breakdown and fully repair each month in 55 
the absence of pregnancy or lactation.  Menstruation is triggered by the withdrawal of the ovarian 56 
steroid hormones, estrogen and progesterone, as the corpus luteum regresses.  This results in a local 57 
inflammatory response, including leukocyte influx and edema, which culminates in tissue breakdown 58 
by matrix metalloproteases and bleeding (1).  Much less is known about the mechanisms and 59 
regulation of endometrial repair, but the processes involved appear to be comparable to classic wound 60 
healing.  These involve temporally overlapping phases of inflammation, resolution of inflammation, 61 
tissue formation, tissue remodeling and angiogenesis.  In the endometrium this repair process appears 62 
to occur in areas of endometrium adjacent to those where breakdown is in progress (2).  Delayed 63 
repair of the endometrium at menstruation may cause prolonged heavy menstrual bleeding (HMB), 64 
which negatively impacts on quality of life for many women.  65 
 66 
Macrophages have a well-established role in the repair process at multiple tissue sites (3).  They 67 
engulf foreign or apoptotic material as part of their phagocytic role and they also secrete a number of 68 
proteases, angiogenic factors and growth factors (4).  Macrophage depletion has been shown to result 69 
in defective repair of skin wounds in the guinea pig (5) and of myocardial injury in mice (6).  70 
Endometrial macrophages are present throughout the menstrual cycle, but display a significant 71 
increase in number during the perimenstrual phase (7).  This increase in the number of tissue resident 72 
macrophages is thought to be dependent upon the increase in concentrations of endometrial cytokines 73 
that occurs in response to progesterone withdrawal. Cytokines have been implicated in both the 74 
recruitment of monocytes into the endometrium and in increased proliferation of macrophages in situ 75 
(7-9).  Recent insights into the phenotype of tissue resident macrophages has revealed that both their 76 
plasticity and the prevailing tissue microenvironment influence the ability to adopt pro-wound-77 
healing, pro-resolving and tissue-regenerating phenotypes after injury, reviewed in (10). 78 
 79 
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CXCL4 (PF4) is a member of the CXC family that has been shown to have a role in chemotaxis of 80 
neutrophils and monocytes (11,12).  It is currently unknown if CXCL4 is an active chemoattractant 81 
within human endometrium but both neutrophils and monocytes are implicated in endometrial repair 82 
(13).  CXCL4 has been shown to induce differentiation of peripheral blood monocytes, characterized 83 
by prevention of spontaneous apoptosis and promotion of differentiation into macrophages in a TNFα 84 
and GM-CSF independent fashion (14).  CXCL4-stimulated differentiation appears to generate a 85 
different macrophage phenotype to the classical M1/M2 subtypes (15).  Notably, these macrophages 86 
lack expression of the scavenger receptor CD163 (15), are unable to up-regulate heme-oxygenase 1 87 
(15) and do not express the HLA-DR antigen (14) but produce more MMP-7 and MMP-12 protein 88 
than other macrophage subtypes (14).  In addition, CXCL4 is known to be an angiostatic factor, 89 
implicated in inhibition of endothelial cell proliferation (16,17).  CXCL4 has been detected at high 90 
concentrations at sites of vascular injury (18) and has been found to down-regulate expression of 91 
MMP-1 and MMP-3 in human vascular endothelial cells, which may contribute to resolution and 92 
repair (19).  93 
 94 
As CXCL4 is thought to have a key role in the regulation of angiogenesis, recruitment of monocytes 95 
and wound healing, we hypothesized that it has a key role in endometrial repair at the time of 96 
menstruation (20).  Therefore, we conducted a comprehensive analysis of human endometrial biopsies 97 
and utilized in vitro cell models to examine the regulation of CXCL4 by steroid hormones including 98 
cortisol, as this steroid is thought to play a key role in regulating the local endometrial environment 99 
during menstruation.  Next, we investigated the impact of CXCL4 on endometrial cells and 100 
macrophages.  Our results highlight a potential role for this cytokine in the physiological processes of 101 
menstruation and endometrial repair.  102 
 103 
  104 
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Methods 105 
 106 
Human endometrial tissue collection 107 
Endometrial biopsies (n=61) were collected with a suction curette (Pipelle, Laboratorie CCD, Paris, 108 
France) from women (median age 42 years, range 22-50) attending gynecological out-patient 109 
departments across NHS Lothian, Scotland.  Written consent was obtained from participants and 110 
ethical approval granted from Lothian Research Ethics Committee (LREC 07/S1103/29).  All women 111 
reported regular menstrual cycles (21-35 days) and no exogenous hormone exposure for 2 months 112 
prior to biopsy.  Women with large fibroids (>3cm) or endometriosis were excluded.  Tissue was 113 
divided and (i) placed in RNA later, RNA stabilization solution (Ambion (Europe) Ltd., Warrington, 114 
UK), (ii) fixed in neutral buffered formalin for wax embedding and (iii) placed in phosphate buffered 115 
saline for in vitro culture.  Cycle stage was determined by (i) histological dating (criteria of Noyes et 116 
al. (21)), (ii) reported last menstrual period and (iii) serum progesterone and estradiol concentrations 117 
at time of biopsy (Table 1). Samples not consistent for all three criteria were excluded (n=5). 118 
 119 
Objective measurement of menstrual blood loss (MBL) 120 
A subset of the participants with biopsies collected in the perimenstrual phase agreed to collect their 121 
sanitary ware to allow objective quantification of their menstrual blood loss (MBL) (n=23).  Women 122 
were provided with the same brand of tampon/pad (Tampax®Always®) and verbal and written 123 
instructions on collection. Blood loss was measured using a modified Alkaline-Haematin method as 124 
previously described (22,23).  A measured MBL of >80ml was classified at heavy menstrual bleeding 125 
(HMB) and <80ml as normal (NMB). This method was validated in our laboratory using time expired 126 
whole blood applied to the same sanitary products given to participants. 127 
 128 
Immunohistochemistry for CXCL4 129 
5μm paraffin sections were dewaxed and rehydrated. Antigen retrieval was by pressure cooker in 130 
sodium citrate pH 6 antigen retrieval buffer. Endogenous peroxidase activity was blocked by 3% 131 
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hydrogen peroxide.  Sections were sequentially incubated in avidin and biotin (Vector Laboratories, 132 
Burlingame, CA, USA) and protein block (Dako, Cambridge, UK).  Rabbit polyclonal CXCL4 133 
antibody (20µg/ml, Abcam, ab9561, Cambridge, UK) was applied overnight at 4°C.  Negative 134 
controls were incubated with Rabbit IgG (Dako) at the same concentration as the primary antibody.  135 
Biotinylated goat anti-rabbit secondary antibody was used at 1:200 (Vector).  Avidin-biotin-136 
peroxidase complex (ABC-Elite; Vector laboratories) was applied for 30 min and liquid 137 
diaminobenzidine (DAB) kit (Zymed Laboratories, San Francisco, CA, USA) used for detection.  The 138 
reaction was stopped with distilled water and sections counterstained with haematoxylin, dehydrated 139 
and mounted with Pertex (Cellpath plc, Hemel Hempstead, UK). 140 
 141 
Semi-quantitative immunoscoring 142 
Localization and intensity of immunostaining was evaluated in the late secretory and menstrual 143 
endometrium of women with objectively measured HMB and NMB by two independent, masked 144 
observers.  The intensity of staining was graded with a three-point scale (0 = no staining, 1 = mild 145 
staining, 2 = strong staining).  This was applied to the stromal compartment and endothelial cells. The 146 
percentage of tissue in each intensity scale was recorded (24).  A value was derived for each of the 147 
cellular compartments by using the sum of these percentages after multiplication by the intensity of 148 
staining. Average scores are reported unless a discrepancy of >50 points occurred between observers, 149 
in these cases the tissue was examined together and a consensus score determined. 150 
 151 
Dual immunofluorescence  152 
Endometrial sections were dewaxed, rehydrated, exposed to antigen retrieval and treated with 3% 153 
hydrogen peroxidase as above.  For CD68/CXCL4 dual immunofluorescence, normal donkey serum 154 
was used as a protein block and the sections were incubated with mouse monoclonal CD68 155 
(macrophage marker) antibody (Dako, Glostrup, Denmark) at a 1 in 1000 dilution overnight at 4°C.  156 
Donkey anti-mouse peroxidase secondary antibody (Abcam, Cambridge, UK) at a 1:750 dilution was 157 
applied for 30 min followed by incubation with TSA™ fluorescein tyramide system (Perkin Elmer, 158 
Waltham, MA., USA) for 10 min.  The sections were incubated with normal donkey serum for 10 min 159 
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followed by 20µg/ml rabbit polyclonal CXCL4 antibody (Abcam) overnight at 4°C.  Alexa 546 160 
donkey anti-rabbit secondary antibody (Invitrogen, Paisley, U.K.) was applied at 1:200 for 1h, 161 
followed by a 4',6-diamidino-2-phenylindole (DAPI) stain (Sigma, Dorset, UK) for 10 min.   162 
CD31/CXCL4 immunofluorescence utilized Novocastra epitope retrieval solution Ph6 (Leica 163 
Microsystems, Wetzlar, Germany) and the Leica Bond-Max automated immunostainer (Leica 164 
Microsystems). Normal goat serum was used as a protein block prior to incubation with CXCL4 165 
antibody (Abcam) at a 1:2000 dilution for 1h at 37C, omission of primary antibody provided negative 166 
controls. Goat anti rabbit secondary antibody (Abcam) was applied before incubation with TSA™ 167 
fluorescein tyramide system (Perkin Elmer) for 10 min. Bond wash was followed by Bond epitope 168 
retrieval system (Leica), block with normal goat serum and incubation with mouse monoclonal CD31 169 
(Novacastra, Milton Keynes, UK) at a 1 in 600 dilution for 1h. Goat anti-mouse secondary antibody 170 
(Abcam) was applied, followed by a 4',6-diamidino-2-phenylindole (DAPI) stain (Sigma, Dorset, UK) 171 
for 10 min. All sections were mounted with Permaflour (Thermo Scientific, Waltham, MA, USA) and 172 
analyzed on a Zeiss LSM710 confocal microscope system. 173 
 174 
Cell culture 175 
Primary human endometrial stromal cells (HESC) were isolated from mid-secretory endometrial 176 
tissue (n=3) by enzymatic digestion as previously described (25).  HESCs at passage <6 were plated 177 
at a density of 106 cells per well in 6 well plates in RPMI medium. Cells were serum starved for 24h 178 
prior to treatments. Cells were treated with (i) 10nM estradiol for 48h, (ii) 1µM cortisol for 48h, (iii) 179 
1µM progesterone for 6 days or (iv) 1µM progesterone for 6 days followed by serum free media for 180 
48h to mimic progesterone withdrawal. 181 
 182 
Human endometrial endothelial cells (HEECs) were a gift from Yale School of Medicine (26).  Their 183 
isolation (27) and phenotype (28) have been previously described.  Serum starved HEECs were 184 
treated in an identical manner to HESCs, described above. 185 
 186 
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Quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) 187 
Concentrations of mRNAs encoded by CXCL4 were determined by RT-qPCR (Taqman) analysis.  188 
Total RNA from cells and endometrial biopsies was extracted using the RNeasy Mini Kit (Qiagen 189 
Ltd, Sussex, UK) according to manufacturer’s instructions: 100ng RNA samples were reverse 190 
transcribed according to standard laboratory protocols (29).  A tube with no reverse transcriptase and 191 
a further tube with water were included as controls.  PCR reaction mixtures were prepared containing 192 
Taqman buffer (5.5mM MgCl2, 200μM dATP 200μM dCTP, 200μM dGTP, 400μM deoxyuridine 193 
triphosphate), ribosomal 18S primers/probe (Applied Biosystems, Warrington, UK) and specific 194 
forward and reverse primers and probes (CXCL4 forward primer agcctggaggtgatcaagg, reverse primer 195 
ccattcttcagcgtggcta, Universal probe library number 43, all from Roche Applied Science, Penzberg, 196 
Germany) were added for each PCR reaction.  Negative controls (water instead of cDNA) were 197 
included in each run.  PCR was carried out using ABI Prism 7900 (Applied Biosystems, Foster city, 198 
CA, USA).  Forty cycles were completed (3s 95C, 30s 60C).  Samples were analyzed in triplicate 199 
using Sequence Detector version 2.3 (PE Biosystems, Foster city, CA, USA), using the comparative 200 
threshold method.  Expression of target mRNA was normalized to RNA loading for each sample 201 
using the 18S ribosomal RNA as a reference.  202 
 203 
In cell Western 204 
Following treatments, cells were fixed with 4% NBF for 15 min prior to incubation with blocking 205 
buffer (PBS, normal goat serum, water and Triton X-100).  Cells were treated with rabbit polyclonal 206 
anti-CXCL4 (1:25 Abcam) and mouse monoclonal anti-β-tubulin (1:1000 Sigma) antibodies 207 
overnight at 4°C.  Cells were washed prior to incubation with goat anti-rabbit IRDye 800CW 208 
(Molecular Probes, Eugene, OR, USA) and goat anti mouse Alexa Fluor 680 (Li-Cor Biosciences, 209 
Lincoln, NE, USA). The LI-COR Odyssey Infrared Imaging System was used to analyze results. 210 
 211 
Macrophage culture 212 
Peripheral blood was obtained from consenting women (LREC 08/S1103/38) on the combined oral 213 
contraceptive pill (n=9) to avoid natural hormone fluctuations and monocytes extracted as previously 214 
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described (9).  Monocytes were cultured into Roswell Park Memorial Institute (RPMI) 1640 medium 215 
(Sigma, St Louis, MO, USA) with M-CSF (216.21nM) treatment for 5 days to differentiate the cells 216 
into macrophages. Macrophages were then treated with 285.71nM GM-CSF (to induce an M0 217 
phenotype), 59.17mM IFNγ (M1 phenotype), 1μM Cortisol (M2 phenotype), Estrogen (10nM) or 218 
Progesterone (10nM) for 24h.  Cells were washed and re-suspended in serum-free RPMI for 24h, 219 
centrifuged, supernatant removed and frozen for use as conditioned media. 220 
 221 
Chemotaxis assay 222 
Microslides (Ibidi, Martinsried, Germany) were coated with collagen according to the manufacturer’s 223 
instructions; collagen was solidified by incubation at 37°C for 30 min. The first well of each capillary 224 
had peripheral blood monocyte derived macrophages (PBMC) in RPMI media (Sigma). The 225 
connecting well had 20ng/ml CXCL4 (Sigma; the half maximal effective concentration (EC50) for 226 
CXCL4 as found by Baltus et al., 2005 (11)) in RPMI media; RPMI alone was used as a negative 227 
control. Movement of PBMCs was measured after 24h using an Axiovert 200 microscope (Ziess).  228 
Distance measured was converted into percentage movement where complete movement would be 229 
100%, and no movement 0%.  The experiment was repeated with PBMCs from 5 different women.  230 
 231 
Statistical Analysis 232 
For cell culture, mRNA results are expressed as fold increase, where relative expression of mRNA 233 
after treatment was divided by the relative expression after vehicle treatment.  For tissue data, results 234 
were expressed as a quantity relative to a comparator, a sample of placental cDNA.  Data are 235 
presented as mean ± SEM and significant differences among raw data (ddCt values) determined using 236 
Kruskal–Wallis non-parametric test with Dunn's multiple comparison post-test. Statistical analysis 237 
between women with HMB and NMB bleeding at different stages of the cycle was determined using a 238 
two-way ANOVA with Bonferroni post-test analysis.  Student’s t-tests were used for immunoscore 239 
data. GraphPad Prism Software was used, version 6 (San Diego, CA, USA). A value of P < 0.05 was 240 
considered significant.  241 
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Results 242 
 243 
CXCL4 mRNA concentrations were increased in menstrual phase human endometrium and 244 
CXCL4 localized to epithelial, stromal, endothelial cells and macrophages. 245 
CXCL4 encoded mRNAs were detected in human endometrial tissue biopsies throughout the cycle an 246 
(Figure 1A).  CXCL4 mRNA concentrations were significantly higher in menstrual biopsies compared 247 
to those from the proliferative (P<0.05), early secretory (P<0.01) and mid secretory phases (P<0.05). 248 
 249 
Immunohistochemistry detected CXCL4 protein in the cytoplasm of epithelial and stromal cells 250 
throughout the menstrual cycle, with an increase in staining intensity noted in endometrium collected 251 
from women during the secretory and menstrual phases (Figure 1B).  Dual immunofluorescence 252 
revealed positive CXCL4 staining in CD31+ endometrial endothelial cells during the late 253 
secretory/menstrual phase (Figure 1B xi). We observed intense immunostaining of occasional cells 254 
within the stromal compartment throughout the cycle. Dual immunohistochemistry revealed CXCL4 255 
was present in the cytoplasm of CD68+ macrophage cells throughout the menstrual cycle (Figure 1C).  256 
 257 
Endometrial CXCL4 was regulated by progesterone withdrawal and cortisol 258 
After confirming the presence of CXCL4 in endometrial stromal and endothelial cells, we examined 259 
its regulation by steroids using primary endometrial stromal cells (HESCs) and a human endometrial 260 
endothelial cell line (HEECs).  Treatment with 10nM estradiol mimicked the proliferative phase, 1µM 261 
progesterone the secretory phase and sequential progesterone treatment and subsequent removal 262 
mimicked the late secretory/menstrual phase.  There is mounting evidence that cortisol has an 263 
important role in the local endometrial environment at menses (9,20); therefore additional cells were 264 
treated with 1µM cortisol.  HESCs undergoing progesterone-withdrawal treatments showed a 265 
significant increase in concentrations of CXCL4 mRNA when compared to those treated with vehicle, 266 
estradiol or cortisol (Figure 2A).  Progesterone withdrawal also significantly increased CXCL4 267 
protein in HESCs when compared to vehicle treated cells (Figure 2B, C). 268 
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 269 
Interestingly, CXCL4 regulation in HEECs was different to that detected in HESCs. Cortisol 270 
treatment of HEECs displayed maximal increases in concentrations of CXCL4 mRNA (Figure 3A) 271 
and protein (Figure 3B, C), which were significantly greater than treatment to mimic progesterone-272 
withdrawal (P<0.01).  273 
 274 
CXCL4 was significantly decreased in endometrial endothelial cells from women with HMB 275 
during the menstrual phase 276 
As CXCL4 mRNA was maximal in endometrium from the late secretory and menstrual phases of the 277 
cycle, we compared mRNA concentrations in endometrial tissue homogenates from these two phases, 278 
taken from women with objectively measured menstrual blood loss (MBL).  Using a blood loss of 279 
>80ml to define HMB, we found no significant differences in mRNA concentrations when comparing 280 
women with HMB and NMB (Figure 4A). 281 
 282 
As we determined that regulation of CXCL4 varied in stromal and endothelial cells in vitro, we 283 
hypothesized that cellular levels of CXCL4 may differ in women with HMB and NMB, despite no 284 
significant differences in global endometrial CXCL4 mRNA concentrations.  We examined CXCL4 285 
protein by immunohistochemistry in endometrium of the late secretory and menstrual phases from 286 
women with NMB and HMB.  Semi-quantitative immunoscoring of the stromal compartment and 287 
endothelial cells revealed no significant changes during the late secretory phase between women with 288 
NMB and HMB (Figure 4B). However, menstrual phase endometrium from women with HMB had 289 
significantly decreased CXCL4 staining of endothelial cells versus tissue from women with NMB 290 
(p<0.05) (Figure 4B, C). In contrast, menstrual stromal compartment staining was not significantly 291 
different in endometrium from women with NMB and HMB.  292 
 293 
CXCL4 has an augmented chemotactic action on macrophages pre-exposed to cortisol 294 
As CXCL4 increased at menses and co-localized to macrophage cells, we investigated the effect of 295 
CXCL4-induced chemotaxis on different macrophage subtypes.  Peripheral macrophages were pre-296 
12 
 
treated to induce different subtypes: M0 (M-CSF pre-treated), M1 (GM-CSF and IFNγ pre-treated) 297 
and M2 (cortisol pre-treated) macrophages, or macrophages exposed to a proliferative phase 298 
environment (estradiol pre-treatment) or exposed to a secretory phase environment (progesterone pre-299 
treated).  These pre-treated macrophages were plated into wells opposite CXCL4 on a multi-300 
channeled microslide. Cortisol-exposed macrophages migrated towards CXCL4 at a significantly 301 
higher rate than any of the other macrophage subtypes (Figure 5A, B). 302 
  303 
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Discussion 304 
 305 
This manuscript details the presence of CXCL4 in the human endometrium across the menstrual cycle 306 
and reveals maximal levels are present during menstruation.  Steroid regulation of CXCL4 occurs in 307 
human endometrial stromal cells, with significant increases following withdrawal of progesterone.  In 308 
contrast, endometrial endothelial cells do not display an increase in CXCL4 on progesterone 309 
withdrawal, but demonstrate significant increases in response to cortisol treatment.  Furthermore, we 310 
reveal that women with HMB have significantly reduced CXCL4 in endothelial cells in the menstrual 311 
phase, consistent with a defective cortisol response at menses (20).  Macrophages pre-treated with 312 
cortisol to induce an M2 phenotype migrate significantly faster towards CXCL4 than M0 and M1 313 
subtypes.  These data are consistent with CXCL4 having a key role in endometrial breakdown and 314 
repair at menstruation. 315 
 316 
CXCL4 is present in the human endometrium during menstruation, with both PCR and 317 
immunohistochemistry being consistent with maximal detection during the menstrual phase. The 318 
functional layer of the endometrial breaks down during menses, with repair occurring simultaneously 319 
in adjacent areas (2).  Therefore, maximal CXCL4 within the endometrium at this time is consistent 320 
with involvement in breakdown and repair of the tissue.  Expression of the CXCL4 receptor, CXCR3, 321 
has been identified as necessary for efficient wound healing (30).  Mice lacking CXCR3 had 322 
significantly delayed re-epithelialization and delayed repair of the basement membrane following 323 
excisional wounds.  324 
 325 
Next, we investigated the regulation of CXCL4 in the human endometrium.  Due to the dramatic 326 
variations observed across the menstrual cycle, we examined steroid regulation of this cytokine. A 327 
series of in vitro studies revealed that progesterone withdrawal resulted in a significant increase of 328 
CXCL4 expression within endometrial stromal cells, consistent with maximal levels during 329 
menstruation.  Human endometrial endothelial cells, however, do not express the progesterone 330 
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receptor (31), hence it was unsurprising that treatment conditions using progesterone or progesterone 331 
withdrawal had no profound effects.  However, human endometrial endothelial cells are known to 332 
express the glucocorticoid receptor (32) and treatment of these cells with cortisol resulted in a 333 
significant increase of CXCL4 expression. We have previously shown that local levels of cortisol 334 
regulating enzymes increase in human endometrial tissue during menstruation (33).  Therefore, two 335 
different steroid hormones have the ability to regulate CXCL4 in endometrial cells to increase 336 
concentrations of this putative wound repair factor during menstruation. 337 
 338 
As CXCL4 is a putative endometrial repair factor, we examined mRNA concentrations in endometrial 339 
tissue sample homogenates from women with HMB and NMB.  We hypothesized that women with 340 
HMB would have reduced CXCL4 induction during menstruation, leading to inefficient endometrial 341 
repair and prolonged, HMB.  However, no significant differences in CXCL4 mRNA concentrations 342 
were detected between these two groups of women during the late secretory or menstrual phases.  343 
There are two potential explanations for these findings.  Firstly, there may be no deregulation of 344 
CXCL4 in women with HMB. However, our results suggested that different cell types within the 345 
human endometrium have differential regulation of CXCL4 induction with progesterone withdrawal 346 
having a significant impact on stromal cells and cortisol regulating CXCL4 in endothelial cells.  347 
Examination of homogenized whole endometrial biopsies may mask differential expression of 348 
CXCL4 within different cell types in women with heavy versus normal menstrual blood loss.  349 
Therefore we examined CXCL4 protein in stromal cells and endothelial cells in women with NMB 350 
and HMB during the late secretory and menstrual phases. This revealed that endothelial cell CXCL4 351 
protein was significantly reduced in women with HMB versus NMB during menses, which might be 352 
consistent with a defective cortisol microenvironment (33).  Our laboratory has previously revealed 353 
that the cortisol-inactivating enzyme 11 beta-hydroxysteroid dehydrogenase-2 is significantly 354 
increased in endometrium from women with HMB versus NMB, thereby creating a local 355 
glucocorticoid deficiency (20).  Therefore, we propose that women with HMB have reduced 356 
endometrial cortisol leading to decreased CXCL4 in endothelial cells which may contribute to 357 
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increased menstrual blood loss. CXCL4 is known to have angiogenic properties (18,19) but its 358 
functional role in the endometrium remains to be determined. 359 
 360 
CXCL4 is known to be a chemoattractant in a number of tissues, triggering migration of monocytes 361 
and macrophages to sites of inflammation (34,35). Herein we show that cortisol treated, M2-like 362 
macrophages exhibit increased chemotaxis towards CXCL4 when compared to other steroid treated 363 
macrophages.  This suggests that the microenvironment created by synthesis of CXCL4 may alter 364 
immune cell components.  It is also notable that cortisol treated macrophages have been documented 365 
to take part in the resolution of inflammation, including removal of apoptotic cells (36).  Taken 366 
together, these data suggest that CXCL4 may act as a chemoattractant at focal points within the 367 
human endometrium that require repair.  368 
 369 
In summary, we have identified that CXCL4 is increased in the human endometrium during 370 
menstruation, a time consistent with involvement in endometrial repair.  Mechanistically, we have 371 
revealed that endometrial CXCL4 is regulated by progesterone withdrawal and cortisol.  In addition, 372 
we reveal that CXCL4 is reduced in endothelial cells of women with HMB at menses.  Functionally, 373 
CXCL4 appears to have a significant role as a macrophage chemoattractant, particularly for 374 
macrophages pre-exposed to cortisol.  These data implicate CXCL4 as a key player in the 375 
physiological process of endometrial repair post menses.  376 
  377 
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Figure Legends 484 
 485 
Figure 1. (A) CXCL4 in whole human endometrial biopsies from across the menstrual cycle reveals 486 
maximal expression during the menstrual phase. Each box represents lower quartile, median and 487 
upper quartile. Whiskers display minimum and maximum values. *P<0.05, **P<0.01.  (B) CXCL4 488 
protein in the human endometrium was localized to the cytoplasm of a few stromal cells during the 489 
proliferative phase (i and ii).  During the early (iii and iv), mid-(v and vi) and late (vii and viii) 490 
secretory phases of the menstrual cycle, immunostaining for CXCL4 progressively increased in 491 
intensity in both the stroma (St) and secretory glandular epithelium (GE). CXCL4 protein was present 492 
throughout the endometrium during the menstrual phase (ix and x) and CXCL4 (green) co-localised to 493 
CD31+ve endothelial cells (red) (xi). Insets = negative controls. Arrows indicate CXCL4 positive 494 
cells. Scale bar 50µm. (C) CXCL4 (green) co-localises to CD68+ve (red) macrophage cells within the 495 
endometrium throughout the menstrual cycle.  Proliferative (i and ii), late secretory (iii and iv), 496 
menstrual (v and vi). Insets show negative controls.  Arrows indicate co-localized cells.  497 
 498 
Figure 2. Steroid regulation of CXCL4 in human endometrial stromal cells (hESCs).  Estrogen, 499 
progesterone, progesterone withdrawal or cortisol treatment of hESCs revealed that progesterone 500 
withdrawal significantly up-regulated (A) CXCL4 mRNA expression (n=5) and (B) CXCL4 protein 501 
levels detected by in cell Western (n=4) and quantified by densitometry (C). Green: CXCL4, Red: β-502 
tubulin; P: progesterone. *p<0.05; **p<0.01. 503 
 504 
Figure 3.  Steroid regulation of CXCL4 in human endometrial endothelial cells (HEECs).  Treating 505 
HEECs with estrogen, progesterone, progesterone-withdrawal, and cortisol found that CXCL4 was 506 
significantly up-regulated by treatment with cortisol at (A) the mRNA level (n=4) and (B) protein 507 
level (n=4), quantified by densitometry (C). Green: CXCL4, Red: β-tubulin; **p<0.01. 508 
 509 
22 
Figure 4. (A) CXCL4 in late secretory and menstrual endometrial biopsies from women with 510 
objectively measured normal (NMB <80ml, white bars) and heavy menstrual bleeding (HMB >80ml, 511 
grey bars). (B) Immunoscoring of CXCL4 staining of the stromal compartment and endothelial cells 512 
in late secretory and menstrual endometrium from women with NMB and HMB.  (C) 513 
Immunohistochemistry staining of CXCL4 in menstrual endometrium from women with NMB and 514 
HMB.  Inset: IgG matched negative control.  Arrow: endothelial cells. LS: late secretory, M: 515 
menstrual, St: stromal compartment. NS non-significant, *p<0.05. 516 
 517 
Figure 5. Cortisol-exposed macrophages show increased migration towards CXCL4. (A) Pre-treated 518 
macrophages (with M-CSF to give an M0 phenotype, GM-CSF and IFNγ to produce an M1 type, 519 
cortisol to give an M2 phenotype, estradiol or progesterone) were plated opposite CXCL4 and 520 
photographed after 24h.  (B) Measuring distance travelled (as a percentage of total distance) 521 
confirmed macrophages pre-treated with cortisol migrated significantly further than other cells. n=5 522 
separate patient samples; *p<0.05. 523 
524 
Table 1. Classification of endometrial biopsies. NMB normal menstrual bleeding, HMB heavy 
menstrual bleeding. MBL menstrual blood loss. 
Stage of Cycle Mean Estradiol 
pmol/l (min-max) 
Mean Progesterone 
nmol/l (min-max) 
NMB MBL  
ml (min-max) 
HMB MBL  
ml (min-max) 
Proliferative 410 (167-679) 2.8 (1.4-4.6) - - 
Early Secretory 439 (289-664) 55.4 (26.6-89.9) - - 
Mid Secretory 585 (301-691) 81.8 (16.1-246.4) - - 
Late Secretory 275 (59-819) 7.5 (1.1-17.0) 48 (35-62) 200 (85-488) 
Menstrual 174 (50-514) 3.4 (1.2-10.6) 40 (26-66) 180 (91-287) 
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